MKI67 Antibody

文獻引用 (2) 說明書

中文名稱：

MKI67兔多克隆抗體
貨號：

CSB-PA11617A0Rb
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human endometrial cancer using CSB-PA11617A0Rb at dilution of 1:100

Immunohistochemistry of paraffin-embedded human bladder cancer using CSB-PA11617A0Rb at dilution of 1:100
其他：

產品詳情
產品評價
引用文獻
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) MKI67 Polyclonal antibody
Uniprot No.：

P46013
基因名：

MKI67
別名：

Antigen identified by monoclonal antibody Ki 67 antibody; Antigen identified by monoclonal antibody Ki-67 antibody; Antigen KI-67 antibody; Antigen KI67 antibody; Antigen Ki67 antibody; KI67_HUMAN antibody; KIA antibody; Marker of proliferation Ki-67 antibody; MIB 1 antibody; MIB antibody; MKI67 antibody; PPP1R105 antibody; Proliferation marker protein Ki-67 antibody; Proliferation related Ki 67 antigen antibody; Protein phosphatase 1 regulatory subunit 105 antibody; RP11-380J17.2 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Proliferation marker protein Ki-67 protein (3120-3256AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，MKI67 Antibody (CSB-PA11617A0Rb)，的標記方式是Non-conjugated。對于MKI67 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA11617B0Rb	MKI67 Antibody, HRP conjugated	ELISA
FITC	CSB-PA11617C0Rb	MKI67 Antibody, FITC conjugated
Biotin	CSB-PA11617D0Rb	MKI67 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

引用文獻

Circ_0001588 Upregulates ERBB4 to Promote Glioma Malignant Progression Through Sponging miR-1281 J Wang,Neurotoxicity research,2023
PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia H Zhang,Cancer cell international,2021

產品評價

靶點詳情

功能：

Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly. Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface. Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility. Binds DNA, with a preference for supercoiled DNA and AT-rich DNA. Does not contribute to the internal structure of mitotic chromosomes. May play a role in chromatin organization. It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed (Probable).
基因功能參考文獻：
1. RAGE, EGFR and Ki-67 were immunohistochemicalyl studied for their expression in biopsy specimens from primary breast tumors PMID: 30139236
2. High Ki-67 expression is associated with Central Giant Cell Granuloma. PMID: 30139237
3. Our results identified FGFR3(high)/Ki67(high) papillary pTa tumors as a subgroup with poor prognosis and encourage histological grading as high grade tumors. PMID: 30154342
4. PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID: 28782638
5. Studies indicate that high Ki-67 expression was correlated with poor prognosis and advanced clinicopathological features, and it could serve as a biomarker for disease management [Review]. PMID: 28287186
6. High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with prostate cancer, at diagnosis. PMID: 29174711
7. the combination of the TERT promoter/BRAFV600E mutations and Ki-67 LI is a promising marker to predict recurrence of PTC. PMID: 28150740
8. p16/Ki-67 dual immunostaining had comparable sensitivity and improved specificity in screening high-grade cervical intraepithelial neoplasm (HGCIN) or CC when compared with hrHPV detection. Further studies may be beneficial to assess the efficacy of this novel biomarker, which can be potentially used as one of the initial screening assays. PMID: 30249873
9. We show that it is possible to approximate the true Ki67 Index accurately without detecting individual nuclei and also statically demonstrate the weaknesses of commonly adopted approaches that use both tumor and non-tumor regions together while compensating for the latter with higher order approximations PMID: 30176814
10. Prognosis of luminal breast carcinoma can be predicted using Ki67 as a continuous variable and a standard cut-off value of 14%. Information about the specimen type used to determine ki67 should be recorded in the pathological report PMID: 28865009
11. Ki-67 and TOPO 2A expression correlated with tumour size and tumour invasiveness in somatotropinomas. PMID: 29334118
12. The aim of this study was to investigate the expression of p16 and SATB1 proteins in regard to expression of the Ki-67 antigen and available clinicopathological data (i.a. receptor status, staging and grading PMID: 29936452
13. Data suggest that Ki-67 is a strong prognostic factor for overall survival (OS) and disease-free survival (DFS) and should be included in all pancreatic neuroendocrine tumor pathology. PMID: 29351120
14. Ki-67-a proliferation marker is easily identified and provides comparable accurate information. In contrast to poor reproducibility of mitotic counts, Ki-67 can achieve high agreement between pathologists; is more reproducible; adds complementary value to the MBR grading system and correlates well with other clinicopathologic parameters. PMID: 29893312
15. High Ki-67 expression is associated with papillary thyroid carcinoma. PMID: 29855303
16. This study demonstrated that p16/Ki-67 dual staining represents an effective method for cervical cancer screening. Application of this method could lead to a reduction of unnecessary colposcopy referrals and misdiagnosis. PMID: 29758205
17. In human adenocarcinoma tissues, PFKFB3 and Ki67 protein levels were related to the clinical characteristics and overall survival PMID: 29327288
18. In leukoplakia, the expression of survivin associated with that of ki-67 reinforces the assumption that all these lesions are potentially malignant. PMID: 28346726
19. High Ki67 expression in the index prostate cancer lesion is an independent predictor of biochemical recurrence in patients with positive surgical margin following radical prostatectomy. PMID: 29506507
20. Ki-67 expression level failed to have a markedly significant impact on survival in patients with extensive-stage small cell lung cancer PMID: 28589765
21. p16/Ki-67 dual staining can increase the efficiency of screening methods for cervical cancer. PMID: 29895125
22. both the value and the level of Ki-67 expression were correlated positively with the normalized iodine concentration (NIC) values (r=0.344, P=0.002 and r=0.248, P=0.026); HIF-1alpha expression was correlated positively with the NIC values of the RC (r=0.598, P<0.001) PMID: 29103468
23. According to immunohistochemistry and immunoblot analysis, the expression levels of cyclin D1, cyclin E, pRb, and Ki67 in psoriasis lesions decreased after treatment and were similar with those in the normal group PMID: 29115643
24. Studies suggest that Ki-67 acts as an organiser of chromosome periphery region [Review]. PMID: 28838621
25. High Ki-67 immunohistochemical expression levels in distant metastatic lesions were independently associated with poorer overall survival outcomes after biopsy of recurrence lesion in breast cancer patients. PMID: 28425014
26. Data show there was no trend to higher Ki-67 antigen in metastatic than primary pancreatic neuroendocrine tumors (NETs). PMID: 28984786
27. Data suggest that Ki-67 antigen proliferative index has important limitations and hhosphohistone H3 (PHH3) is an alternative proliferative marker. PMID: 29040195
28. A high Ki-67 LI correlated significantly with a worse prognosis in gastric cancer (GC)patients. Further cumulative studies for the optimal cutoff value for high Ki-67 LI are needed before application in clinical practice. PMID: 28561880
29. Ki67 expression in gastric carcinoma is directly correlated with the tumor grade and depth of invasion. PMID: 28965621
30. In ACTH-secreting pituitary tumors, Ki-67 was expressed in 7 of 28 recurrent tumors and 8 of 27 nonrecurrent tumors, and there was no staining in normal pituitary samples. It was expressed predominantly in the nucleus of the tumor cells. There was no significant difference between Ki67 expression between the nonrecurrent group and the recurrent group. PMID: 29432944
31. Adjuvant chemotherapy was 9% less likely to be recommended by a multidisciplinary board when using the current criteria compared with using a combination of the St. Gallen criteria and Ki67 and uPA/PAI-1 status (P = 0.03). Taken together, our data show discordance among markers in identifying the risk of recurrence, even though each marker may prove to be independently valid. PMID: 28954632
32. The different values of the cycling nuclear area major dimension may also be connected with the biological behaviour of the three examined groups. Moreover, the endometrial epithelial cells may follow a Ki-67 increase pathway, instead of the relatively stable pathway which the rapidly proliferating adenocarcinoma cells may use. PMID: 28737230
33. Age-associated expression of the proliferation and immature neuron markers MKI67 and DCX, respectively, was unrelated, suggesting that neurogenesis-associated processes are independently altered at these points in the development from stem cell to neuron. PMID: 28766905
34. High Ki-67 expression in localized PCa is a factor of poor prognosis for prostate cancer PMID: 28648414
35. Dual p16 and Ki-67 expression can be used in cervical screening of HPV-positive women. PMID: 29566392
36. The expression of alpha-enolase, Ki67 and p53 in pancreatic cancer and adjacent normal tissues were evaluated by IHC using the corresponding primary antibodies on the commercial tissue arrays PMID: 28824297
37. All cases of DF showed much higher Ki67 proliferation index (P = 0.0001) along with increased mitotic figures both on H&E and with anti-PHH3 PMID: 28609344
38. We performed immunohistochemistry for Ki67, p16INK4a, and WNT5A in human HPs ( hyperplastic polyps), sessile serrated adenomas/polyps (SSA/Ps), and traditional serrated adenomas (TSAs) .The distribution of Ki67 and p16INK4a positive cells in TSAs was different from that in HPs and SSA/Ps. PMID: 28627675
39. Ki-67 expression in ureteroscopic biopsy specimens is potentially helpful in clinical decision making for patients with suspected upper urinary tract urothelial carcinoma. PMID: 28554752
40. For patients with ER+/HER2- breast cancer, three distinct risk patterns by Ki67-LI levels were confirmed according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information. PMID: 28061893
41. Data suggest that Ki-67 index and survivin may be useful biomarkers for rectal cancer with preoperative chemoradiotherapy. PMID: 29491110
42. IHC based post-Ki67 levels may have distinct predictive power compared with the naive IHC Ki67. PMID: 28412725
43. Ten international pathology institutions participated in this study and determined messenger RNA expression levels of ERBB2, ESR1, PGR, and MKI67 in both centrally and locally extracted RNA from formalin-fixed, paraffin-embedded breast cancer specimens with the MammaTyper(R) test. Samples were measured repeatedly on different days within the local laboratories, and reproducibility was assessed by means of variance comp... PMID: 28490348
44. Our data support Ki67 evaluation to estimate non-small-cell lung cancer (NSCLC) patients' prognosis, particularly for adenocarcinoma. PMID: 26272457
45. p16/Ki-67 co-expressions associated strongly with high-risk human papillomavirus persistence, especially with HPV16/18, and could be considered as a suitable biomarker for cervical cancer screening PMID: 27588487
46. high expression of VEGF and Ki-67 were independent poor prognostic factors for overall survival in adenoid cystic carcinoma PMID: 26194375
47. Proliferative markers-mitotic count and Ki67 index-have limited value to predict recurrence or metastasis in congenital mesoblastic nephromas with a cellular component PMID: 27484189
48. KI-67 expression correlates with SATB1 expression in non-small cell lung carcinoma. PMID: 29374696
49. Ki-67 may be of diagnostic value in distinguishing between partial and complete hydatidiform moles PMID: 29374747
50. Ki-67 proliferation index (P = 0.027) proved to be independent prognostic factors PMID: 27049832
顯示更多

收起更多
亞細胞定位：

Chromosome. Nucleus. Nucleus, nucleolus.
數據庫鏈接：

HGNC: 7107

OMIM: 176741

KEGG: hsa:4288

STRING: 9606.ENSP00000357643

UniGene: Hs.689823

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human